Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease—A Real World Retrospective Study from India
International Journal of Clinical Metabolism and Diabetes · 2025
DOI: 10.1177/30502071241281419 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Metabolism and Diabetes, 2025. Verfasst von Krishna G. Seshadri und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Aims
Several studies support type 2 diabetes mellitus (T2DM) as one of the risk factors of metabolic dysfunction associated steatotic liver disease (MASLD). Recently, the use of pioglitazone and sodium-glucose co-transporter 2 inhibitors (SGLT2i) has been on the rise considering its beneficial effects in reducing liver dysfunction. We aim to determine the clinical effectiveness of these drugs in improving MASLD and T2DM. Materials and methods: We conducted a retrospective study of 279 T2DM patients with MASLD who were prescribed pioglitazone and/or SGLT2i from two clinics in India. The primary endpoint was change in fibrosis (FIB-4) index and the aspartate aminotransferase to platelet ratio index (APRI) score at one year follow-up. Appropriate statistical tests were applied to assess the significance of the outcomes.
Results
Of the total (276) patients, 46% of patients were at low risk of advanced fibrosis, 11% were at high risk for advanced fibrosis, and the majority (50%) were on SGLT2i treatment. At follow-up, there is a statistically significant reduction in the mean (SD) FIB-4 index (1.92 [1.22] vs. 1.68 [0.99]) and APRI score (0.42 [0.34] vs. 0.33 [0.21]); p < .001. Among treatment groups, there is a significant difference in the mean FIB-4 index both at baseline (F: 4.23; p < .05) and follow-up (F: 3.45; p < .05). These scores were highly significant in the combination treatment with SGLT2i and pioglitazone ( p < .05).
Conclusions
Our results indicate a combination therapy with SGLT2i and pioglitazone might be beneficial in managing MASLD, especially in reducing the FIB-4 index and APRI score in Indian T2DM patients with MASLD.
Zitieren
APA
Seshadri, K. G., Padhye, D., Tippisetty, S., Polisetti, S., & Gadia, S. (2025). Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease—A Real World Retrospective Study from India. International Journal of Clinical Metabolism and Diabetes. https://doi.org/10.1177/30502071241281419
Vancouver
Seshadri KG, Padhye D, Tippisetty S, Polisetti S, Gadia S. Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease—A Real World Retrospective Study from India. International Journal of Clinical Metabolism and Diabetes. 2025. doi:10.1177/30502071241281419
BibTeX
@article{Seshadri2025,
author = {Seshadri, Krishna G. and Padhye, Dakshata and Tippisetty, Surekha and Polisetti, Subhadra and Gadia, Smriti},
title = {Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease—A Real World Retrospective Study from India},
journal = {International Journal of Clinical Metabolism and Diabetes},
year = {2025},
doi = {10.1177/30502071241281419}
}
EUVIMED